Alka Agrawal

Title: Alka Agrawal: Innovator in Antibody Development

Introduction

Alka Agrawal is a prominent inventor based in Cambridge, MA, known for her significant contributions to the field of biotechnology. She has developed innovative solutions that address critical health challenges, particularly in the area of autoimmune disorders.

Latest Patents

Alka Agrawal holds a patent for "Anti-Kv1.3 antibodies, and methods of production and use thereof." This patent focuses on anti-Kv1.3 antibodies, specifically monoclonal antibodies (mAbs) that bind to Kv1.3 with high affinity and inhibit its function. The patent includes detailed amino acid sequences of the complementarity-determining regions (CDRs) of both light and heavy chains of these antibodies. It also provides canonical structures for CDRs in the variable heavy (VH) and variable light (VL) regions. Furthermore, the patent discloses nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, and methods for producing and expressing these antibodies. The therapeutic applications of these mAbs, particularly in preventing or treating autoimmune disorders, are also highlighted.

Career Highlights

Alka Agrawal is currently associated with Tetragenetics, Inc., where she continues to advance her research and development efforts. Her work has positioned her as a key figure in the biotechnology sector, contributing to innovative therapeutic solutions.

Collaborations

Alka has collaborated with notable colleagues, including Paul A. Colussi and Janna Bednenko, who have supported her research endeavors and contributed to the development of her patented technologies.

Conclusion

Alka Agrawal's innovative work in the development of anti-Kv1.3 antibodies showcases her commitment to advancing medical science and improving therapeutic options for patients with autoimmune disorders. Her contributions are a testament to the impact of dedicated inventors in the field of biotechnology.